Trending: GSK Vaccine For RSV Gets Authorization in Europe
June 07 2023 - 2:45PM
Dow Jones News
2:14 p.m. ET -- GSK is one of the most mentioned companies in
the U.S. across all news items in the last 12 hours, according to
Factiva data. The European Commission on Wednesday European
Commission has authorized the company's Arexvy, a respiratory
syncytial virus vaccine, for use in Europe. GSK said RSV, a common,
contagious respiratory virus, leads to over 270,000
hospitalizations and about 20,000 in-hospital deaths each year in
adults aged 60 years and over in Europe. Dow Jones & Co. owns
Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
June 07, 2023 14:30 ET (18:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024